<i>Shigella</i> OspF blocks rapid p38-dependent priming of the NAIP–NLRC4 inflammasome
The NAIP-NLRC4 inflammasome senses pathogenic bacteria by recognizing the cytosolic presence of bacterial proteins such as flagellin and type III secretion system (T3SS) subunits. In mice, the NAIP-NLRC4 inflammasome provides robust protection against bacterial pathogens that infect intestinal epithelial cells, including the gastrointestinal pathogen <i><i>Shigella</i> flexneri</i>. By contrast, humans are highly susceptible to <i><i>Shigella</i></i>, despite the ability of human NAIP-NLRC4 to robustly detect <i><i>Shigella</i></i> T3SS proteins. Why the NAIP-NLRC4 inflammasome protects mice but not humans against <i><i>Shigella</i></i> infection remains unclear. We previously found that human THP-1 cells infected with <i><i>Shigella</i></i> lose responsiveness to NAIP-NLRC4 stimuli, while retaining sensitivity to other inflammasome agonists. Using mT3Sf, a "minimal <i><i>Shigella</i></i>" system, to express individual secreted <i><i>Shigella</i></i> effector proteins, we found that the OspF effector specifically suppresses NAIP-NLRC4-dependent cell death during infection. OspF was previously characterized as a phosphothreonine lyase that inactivates p38 and ERK MAP kinases. We found that p38 was critical for rapid priming of NAIP-NLRC4 activity, particularly in cells with low NAIP-NLRC4 expression. Overall, our results provide a mechanism by which <i><i>Shigella</i></i> evades inflammasome activation in humans, and describe a mechanism for rapid priming of the NAIP-NLRC4 inflammasome.
Authors
- Patrick S. Mitchell (ORCID: https://orcid.org/0000-0001-8375-9060)
- Elizabeth A Turcotte (ORCID: https://orcid.org/0000-0002-0165-7173)
- Lisa Goers (ORCID: https://orcid.org/0000-0002-1585-8726)
- Daniel E. Zak (ORCID: https://orcid.org/0000-0002-1404-400X)
- Kyungsub Kim (ORCID: https://orcid.org/0000-0003-2897-0220)
- Kevin Eislmayr (ORCID: https://orcid.org/0000-0001-7440-4671)
- Cammie F. Lesser (ORCID: https://orcid.org/0000-0002-1702-6333)
Institutions
- Tufts University (US)
- Drugs for Neglected Diseases Initiative (CH)
- Harvard University (US)
- Cancer Research Institute (US)
- University of Washington (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Proceedings of the National Academy of Sciences
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1073/pnas.2510950123
- Citations
- 2
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 44.47
Funders
- National Science Foundation
- University of Pennsylvania
- National Institutes of Health